Phase I Study of Selinexor a Selective Inhibitor of Nuclear Export in Combination With Fludarabine and Cytarabine in Pediatric Relapsed or Refractory Acute Leukemia

摘要

PurposeTo characterize the toxicity, pharmacokinetics, and pharmacodynamics of selinexor, a selective inhibitor of nuclear export, when combined with fludarabine and cytarabine, in children with relapsed or refractory leukemia.